On September 6, 2018 Gibson Oncology, LLC ("Gibson"), a privately held clinical stage company, reported that it acquired three (3) clinical non-camptothecin Topoisomerase I drugs from Linus Oncology (Press release, Gibson Oncology, SEP 6, 2018, View Source [SID1234532059]). These novel anti-cancer drugs have been tested in over 70 patients by the National Cancer Institute (NCI) and have been shown to be both safe and effective in phase I clinical trials. There are multiple United States and international patents on these agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The compounds acquired are indenoisoquinolines ("indenos"), a novel class of drugs which were invented and developed by Purdue University and the NCI to minimize the diarrhea and neutropenia associated with the administration of traditional camptothecin agents such as irinotecan and topotecan. The multiple phase I trials have shown effectiveness in end-stage cancer patients with solid tumors who had failed administration of up to nine (9) drugs given previously. Simultaneously, these new drugs dramatically reduce the incidence of grade 3 and 4 neutropenia and diarrhea.

In addition, Gibson strengthened its Indeno product platform through obtaining an exclusive, worldwide development and commercialization license from Purdue University for the recently discovered pro-drugs for this novel class of compounds.

With pre-clinical studies already performed which demonstrate both the effectiveness of indenos after the development of irinotecan resistance as well as synergy between PARP inhibitors and the indenos, Gibson intends to approach the FDA about phase II studies. Several academic organizations, both in the United States and in Europe, have approached Gibson about helping conduct these studies.

"We are excited to advance these novel, potent, and well-tolerated small molecule topoisomerase I inhibitor drugs in advanced stage and/or resistant cancers as a single agent or in combination with immune-oncology and targeted therapies for improved patient outcomes," stated Randall Riggs, CEO of Gibson Oncology, LLC.

On September 6, 2018 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, reported that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the company’s clinical development program (Press release, Oncolytics Biotech, SEP 6, 2018, View Source [SID1234534182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The supply agreement enables us to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab," said Dr. Matt Coffey President and CEO of Oncolytics Biotech. "We plan on incorporating this anti-PD-L1 cancer immunotherapy into our clinical program immediately. Data from these studies will broaden our experience with this drug class as we look to demonstrate the impact of pelareorep with checkpoint inhibitors."

Under this five-year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.

On September 6, 2018 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that it has entered into a strategic collaboration with Moffitt Cancer Center to develop multi‑targeted chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with AML and B‑cell malignancies (Press release, Atara Biotherapeutics, SEPT 6, 2018, View Source [SID1234529322]). As part of the collaboration, Atara will gain access to novel CAR T targeting and co‑stimulation domains designed to improve T cell proliferation and enhance persistence. This agreement, along with Atara’s prior CAR T collaboration with Memorial Sloan Kettering Cancer Center (MSK), furthers the Company’s strategy to develop next generation engineered CAR T immunotherapies across multiple therapeutic areas and leverage the Company’s off-the-shelf, allogeneic T-cell immunotherapy platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Atara is a leader in the development of off-the-shelf, allogeneic T-cell immunotherapies based on their novel EBV-specific T-cell technology platform," said Marco Davila, M.D., Ph.D., medical oncologist in the Department of Blood and Marrow Transplantation and Medical Director of the GMP Cell Production Facility, Moffitt Cancer Center. "I look forward to rapidly advancing our CAR T engineering and multi-antigen targeting technologies with Atara to address the high unmet need in patients with advanced AML and B-cell malignancies."

Under the agreement, Atara will collaborate with Dr. Davila to develop multi-targeted CAR T immunotherapies designed to address cancers with diverse cell types that often become resistant to treatment such as AML and B-cell malignancies. In addition, the collaboration includes the use of novel CAR T intracellular co-stimulatory domains based on CD28 and 4-1BB that may improve CAR T proliferation when responding to an appropriate antigen and enhance CAR T persistence by reducing T cell exhaustion.

Dietmar Berger, M.D., Ph.D., Global Head of Research and Development of Atara Biotherapeutics said, "Our focus is to rapidly advance development of next generation off-the-shelf, allogeneic CAR T immunotherapies across multiple therapeutic areas by combining our EBV-specific T-cell platform, development, manufacturing and regulatory expertise with cutting edge T-cell engineering discoveries by our external collaborators. Our new strategic collaboration with Moffitt Cancer Center builds our novel CAR T preclinical pipeline and has the potential to benefit patients with myeloid and B cell malignancies."

James J. Mulé, Ph.D., Associate Center Director, Translational Research, and Director of Cell-Based Immunotherapies, Moffitt Cancer Center added, "Atara is a strong technology and development partner. The Company’s clinically advanced EBV-specific T-cell technology platform is complementary to Moffitt’s CAR T engineering and multi-antigen targeting technologies. I look forward to following the progress of Dr. Davila and Atara to develop the next generation of CAR T immunotherapies."

Under the terms of the agreement, Atara will contribute resources and relevant experience to the research activities at Moffitt. Further terms of the agreement were not disclosed.

On September 6, 2018 LabCorp (NYSE: LH) reported it will participate at the Morgan Stanley Global Healthcare Conference (Press release, LabCorp, SEP 6, 2018, View Source;p=RssLanding&cat=news&id=2366346 [SID1234529384]). LabCorp’s presentation is planned for Thursday, September 13, 2018 at 2:05 pm (ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay

On September 6, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will give a company update at the Morgan Stanley 16th Annual Global Healthcare Conference in New York, New York at 2:15 PM EDT / 8:15 PM CEST on September 12, 2018 (Press release, Genmab, SEPT 6, 2018, View Source [SID1234529323]). A webcast of the update, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!